Optogenetic dissection of striatal circuits in a mouse model of human dystonia

人类肌张力障碍小鼠模型纹状体回路的光遗传学解剖

• 批准号: 8924030
• 负责人: Alexandra Nelson
• 金额: $ 17.15万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-08 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8924030
• 关键词: Address; Animal Model; Animals; Applications Grants; Area; Basal Ganglia; Behavioral; Biochemical; Brain; Brain Injuries; Cells; Clinical; Corpus striatum structure; Development; Disease; Dissection; Doctor of Philosophy; Dyskinetic syndrome; Dystonia; Electromyography; Electrophysiology (science); Functional disorder; Future; Genes; Genotype; Health; Human; Hyperactive behavior; In Vitro; Inherited; Laboratories; Lead; Learning; Light; Long-Term Depression; Long-Term Potentiation; Mentors; Modeling; Monitor; Movement; Movement Disorders; Mus; Nature; Neurologic; Neurology; Neurons; Paroxysmal Dystonia; Pathway interactions; Patients; Pattern; Phenotype; Physicians; Physiological; Population; Primary Dystonias; Research; Research Personnel; Research Proposals; Resources; Role; Scientist; Secondary Dystonia; Site; Slice; Structure; Symptoms; Synapses; Synaptic plasticity; Techniques; Testing; Time; Training; Transgenic Mice; Whole-Cell Recordings; Wild Type Mouse; awake; base; career; career development; comparative efficacy; fluorophore; human disease; in vivo; mouse model; nervous system disorder; neural patterning; neuropathology; neurophysiology; neurotransmission; new therapeutic target; novel; optogenetics; post-doctoral training; relating to nervous system; skills; theories; therapeutic development; therapy development; tool

DESCRIPTION (provided by applicant): Primary dystonias are disabling neurological conditions which begin in the prime of patients' lives. Scientists have identified genes involved i some inherited forms of the disease, but little is known about the pathophysiology, and at present treatments is limited and symptomatic in nature. As the brains of such patients show no neuropath logical abnormalities, it is hypothesized that dystonia is a disease of abnormal circuit activity. This proposal is aimed at dissecting the circuitry of one of the key movement control centers, the striatum, in a mouse model of dystonia. In examining the striatal circuitry, we hope to identify new targets for therapeutic development in dystonia as well as other hyperkinetic movement disorders. We propose to use several novel tools to better understand circuit dysfunction in dystonia. First, we plan to use a new mouse model of a human dystonia, paroxysmal nonkinesigenic dyskinesia (PNKD), which is one of very few animal models that recapitulate the clinical features of human dystonia. Second, we plan to employ a new experimental tool, ontogenetic, which allows researchers to control the activity of specific cell populations in the brain. In Aim 1, we will use ontogenetic and in vivo electrophysiology to identify the pathological firing patterns of striatal neurons in awake-behaving PNKD mice, and for the first time distinguish how differences in the activity of direct-pathway and indirect- pathway neurons contribute to dystonia. In Aim 2, we will use in vitro electrophysiology to determine the cellular and synaptic substrate for the pathological firing patterns identified in PNKD mice in vivo. Finally, in Aim 3, we will take what we have learned from both in vivo and in vitro studies of dystonic mice to determine what aspects of aberrant striatal activity are necessary and sufficient to cause dystonia, by using ontogenetic in behaving animals. We will also ontogenetically modify striatal firing patterns to reduce or eliminate the symptoms of dystonia in PNKD mice. Overall, we are hopeful this line of research will not only shed light on long-held theories about basal ganglia circuit dysfunction in dystonia, but will yield new areas fo therapeutic development. I am a physician-scientist with a strong commitment to a career in academic neurology, focused on identifying the circuit basis of neurological disease. I combine PhD and postdoctoral training in neurophysiology with subspecialty training in behavioral neurology and movement disorders. The career development entailed in this research proposal will bring my skills into mouse models of neurological disease and cultivate cutting-edge neurophysiological and optogenetic techniques as a means of understanding and disrupting abnormal patterns of neural activity. The mentoring entailed in this proposal will provide me the scientific and professional resources to continue my own development as an investigator, enabling me to submit competitive grant applications and lead my own laboratory in the future.

描述（由申请人提供）：原发性肌张力障碍是在患者生命的黄金时期开始的致残性神经系统疾病。科学家们已经确定了与一些遗传形式的疾病有关的基因，但对病理生理学知之甚少，目前的治疗是有限的，本质上是症状性的。由于这类患者的大脑未表现出神经性异常，因此假设肌张力障碍是一种神经回路活动异常的疾病。这一建议的目的是解剖一个关键的运动控制中心，纹状体的电路，在一个小鼠模型的肌张力障碍。在检查纹状体回路时，我们希望为肌张力障碍和其他多动运动障碍的治疗开发找到新的靶点。我们建议使用一些新的工具来更好地理解肌张力障碍中的电路功能障碍。首先，我们计划使用一种新的人类肌张力障碍小鼠模型，即阵发性非运动性运动障碍（PNKD），这是为数不多的能够概括人类肌张力障碍临床特征的动物模型之一。其次，我们计划采用一种新的实验工具，本体发生，它允许研究人员控制大脑中特定细胞群的活动。在Aim 1中，我们将使用个体发生和体内电生理学来识别清醒行为PNKD小鼠纹状体神经元的病理放电模式，并首次区分直接通路和间接通路神经元活动的差异如何导致肌张力障碍。在目的2中，我们将使用体外电生理学来确定PNKD小鼠体内病理放电模式的细胞和突触底物。最后，在Aim 3中，我们将从体内和体外对肌张力障碍小鼠的研究中了解到，通过对行为正常的动物进行个体发生研究，确定纹状体异常活动的哪些方面是引起肌张力障碍的必要和充分条件。我们还将从个体遗传学角度修改纹状体放电模式，以减少或消除PNKD小鼠肌张力障碍的症状。总的来说，我们希望这条研究路线不仅将阐明长期以来关于肌张力障碍的基底神经节回路功能障碍的理论，而且将为治疗发展带来新的领域。我是一名内科科学家，致力于学术神经病学的职业生涯，专注于识别神经系统疾病的电路基础。我将神经生理学的博士和博士后训练与行为神经学和运动障碍的亚专业训练相结合。这项研究计划所涉及的职业发展将使我的技能应用于神经疾病的小鼠模型，并培养尖端的神经生理学和光遗传学技术，作为理解和破坏神经活动异常模式的手段。这份提案所包含的指导将为我提供科学和专业的资源，以继续我作为研究者的发展，使我能够在未来提交有竞争力的资助申请并领导自己的实验室。